Evidence map›Paper›PMID 30092042›Full record

ArticlePloS one2018

The neurofilament derived-peptide NFL-TBS.40-63 enters in-vitro in human neural stem cells and increases their differentiation.

Kristell Barreau, Claudia Montero-Menei, Joël Eyer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kristell BarreauLaboratoire Micro et Nanomédecines Translationnelles, Inserm 1066, CNRS 6021, Institut de Recherche en Ingénierie de la Santé, Bâtiment IBS Institut de Biologie de la Santé, Université Angers, Centre Hospitalier Universitaire, Angers, France.
Claudia Montero-MeneiCentre de Recherche en Cancérologie et Immunologie, INSERM, Université de Nantes, Université Angers, Angers, France.
Joël EyerLaboratoire Micro et Nanomédecines Translationnelles, Inserm 1066, CNRS 6021, Institut de Recherche en Ingénierie de la Santé, Bâtiment IBS Institut de Biologie de la Santé, Université Angers, Centre Hospitalier Universitaire, Angers, France.ORCID 0000-0001-6301-7465
Centre National de la Recherche Scientifique · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regenerative medicine is a promising approach to treat neurodegenerative diseases by replacing degenerating cells like neurons or oligodendrocytes. Targeting human neural stem cells directly in the brain is a big challenge in such a strategy. The neurofilament derived NFL-TBS.40-63 peptide has recently been introduced as a novel tool to target neural stem cells. Previous studies showed that this peptide can be internalized by rat neural stem cells in vitro and in vivo, which coincided with lower proliferation and self-renewal capacity and increase of differentiation. In this study, we analyzed the uptake and potential effects of the NFL-TBS.40-63 peptide on human neural stem cells isolated from human fetuses. We showed that the peptide inhibits proliferation and the ability to produce neurospheres in vitro, which is consistent with an increase in cell adhesion and differentiation. These results confirm that the peptide could be a promising molecule to target and manipulate human neural stem cells and thus could serve as a strategic tool for regenerative medicine.

Indexed as

Regenerative MedicineCell AdhesionCell CycleCell DifferentiationCell ProliferationCells, CulturedFetusHumansMicrotubulesNeural Stem CellsNeurofilament ProteinsPeptide FragmentsNeurofilament ProteinsNFL-TBS.40-63 peptidePeptide Fragments

Identifiers

PMID30092042
PMCPMC6084907
OpenAlexW2887485159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.